Many researches have demonstrated that MDM2-p53 inhibitors could upregulate MDM2 expression levels in wild-type p53 cancer cells, our work also finds XR-2 upregulates MDM2 levels in PCa cells, therefore, promoting MDM2-regulated AR and ARV7 degradation through proteasome pathway. This evidence concerns the gene TP53 and cancer.